Lipid-based dispersions of exemestane for improved dissolution rate and intestinal permeability: in vitro and ex vivo characterization
Source abstract
Abstract
Current study aimed to develop lipid dispersions of poorly water soluble exemestane by employing lipid carriers such as Gelucire 44/14 and TPGS with porous calcium silicate (PCS) as an adsorbent carrier and formulate into a solid dosage form. The lipid dispersions at 1:5 ratio showed the highest solubility and dissolution compared to pure exemestane. Further, the ex vivo intestinal permeation studies showed improved apparent permeability (Papp, cm/s) of exemestane from the lipid dispersions (GLD1:5 1.3 × 10−2 cm/s; TLD1:5 1.8 × 10−2 cm/s) compared to pure exemestane (0.7 × 10−2 cm/s). The optimized lipid dispersions (GLD1:5 and TLD1:5) were evaluated for scalability to develop into capsules.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Drug Solubulity and Delivery Systems · Advanced Drug Delivery Systems · Analytical Methods in Pharmaceuticals
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, St. Peter’s Institute of Pharmaceutical Sciences, Vidyanagar, Warangal, Telangana, India
Funding
Science and Engineering Research Board
References (41)
Show source-provided references
1. 10.1007/s12247-014-9181-610.1007/s12247-014-9181-6 ↗
2. 10.1007/s11814-012-0133-x10.1007/s11814-012-0133-x ↗
3. 10.1016/j.tca.2005.09.01110.1016/j.tca.2005.09.011 ↗
4. Carr RL. · Chem Eng · 1965 · 72 · 163
5. 10.1023/A:101500050362910.1023/A:1015000503629 ↗
6. 10.4155/tde.15.4310.4155/tde.15.43 ↗
7. 10.1007/s40005-013-0069-010.1007/s40005-013-0069-0 ↗
8. 10.3109/03639045.2013.80198410.3109/03639045.2013.801984 ↗
9. 10.1002/jps.2266610.1002/jps.22666 ↗
10. 10.1016/j.bbalip.2008.05.00610.1016/j.bbalip.2008.05.006 ↗
11. 10.1002/jps.2397910.1002/jps.23979 ↗
12. 10.3109/10837450.2014.90830610.3109/10837450.2014.908306 ↗
13. 10.1016/j.jsbmb.2007.05.02310.1016/j.jsbmb.2007.05.023 ↗
14. 10.1016/S0378-5173(01)00891-210.1016/S0378-5173(01)00891-2 ↗
15. Higuchi J · Adv Anal Chem Instrum · 1965 · 4 · 117
16. 10.1016/j.ejps.2015.03.02410.1016/j.ejps.2015.03.024 ↗
17. 10.1007/s40005-013-0060-910.1007/s40005-013-0060-9 ↗
18. 10.1016/j.farmac.2005.04.01410.1016/j.farmac.2005.04.014 ↗
19. 10.1200/JCO.2000.18.7.139910.1200/JCO.2000.18.7.1399 ↗
20. 10.1002/jps.2006710.1002/jps.20067 ↗
21. 10.1016/S0378-5173(00)00485-310.1016/S0378-5173(00)00485-3 ↗
22. Kristina SB · J Pharm Pharm Sci · 2007 · 10 · 319
23. 10.1016/S0939-6411(00)00091-610.1016/S0939-6411(00)00091-6 ↗
24. 10.1016/j.supflu.2006.03.02710.1016/j.supflu.2006.03.027 ↗
25. 10.1016/j.ijpharm.2014.11.00110.1016/j.ijpharm.2014.11.001 ↗
26. 10.1016/j.ijpharm.2010.12.03510.1016/j.ijpharm.2010.12.035 ↗
27. 10.1016/j.apt.2010.09.01810.1016/j.apt.2010.09.018 ↗
28. 10.3109/03639045.2014.90008110.3109/03639045.2014.900081 ↗
29. 10.1021/js980403l10.1021/js980403l ↗
30. 10.1016/S0168-3659(02)00492-310.1016/S0168-3659(02)00492-3 ↗
31. 10.1208/s12249-008-9080-610.1208/s12249-008-9080-6 ↗
32. 10.1007/s11814-015-0205-910.1007/s11814-015-0205-9 ↗
33. 10.1023/A:101216741037610.1023/A:1012167410376 ↗
34. van den Mooter G · Int J Pharm Sci · 2006 · 26 · 219
35. 10.1002/chin.20074527010.1002/chin.200745270 ↗
36. Yavuz B · FABAD J Pharm Sci · 2007 · 32 · 79
37. 10.1016/j.ijpharm.2010.07.04610.1016/j.ijpharm.2010.07.046 ↗
38. 10.1023/A:101893900678010.1023/A:1018939006780 ↗
39. 10.1248/cpb.42.232710.1248/cpb.42.2327 ↗
40. 10.1016/S0939-6411(03)00142-510.1016/S0939-6411(03)00142-5 ↗
41. 10.1016/j.ijpharm.2014.01.02310.1016/j.ijpharm.2014.01.023 ↗